ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated… [Read More]

ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area,… [Read More]

Click on images to view larger ROCKVILLE, Md., July 28, 2020 — American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from… [Read More]

ROCKVILLE, MD, January 8, 2020 – American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the 38th annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 12-16 in San Francisco, California. American Gene Technologies’ second invitation… [Read More]

ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the… [Read More]